Cargando…

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma

Evofosfamide (Evo or TH302) is a hypoxia-activated prodrug which is reduced leading to the release of alkylating agent bromo-isophosphoramide mustard, which has shown safety and signals of efficacy in a prior phase 1 study in recurrent glioblastoma. We performed a dual center single-arm Phase II stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brenner, Andrew J., Floyd, John, Fichtel, Lisa, Michalek, Joel, Kanakia, Kunal P., Huang, Shiliang, Reardon, David, Wen, Patrick Y., Lee, Eudocia Quant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841164/ https://www.ncbi.nlm.nih.gov/pubmed/33504881 http://dx.doi.org/10.1038/s41598-021-81841-0

Ejemplares similares

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET
por: Huang, Shiliang, et al.
Publicado: (2021)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect()()
por: Hong, Cho Rong, et al.
Publicado: (2018)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
por: Wojtkowiak, Jonathan W, et al.
Publicado: (2015)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016)

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
por: Harms, Julia K., et al.
Publicado: (2019)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

Evaluation of the “Steal” Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer
por: Bailey, Kate M., et al.
Publicado: (2014)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
por: Weiss, Glen J., et al.
Publicado: (2011)

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition
por: Meng, Fanying, et al.
Publicado: (2015)

Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas
por: Yoon, C, et al.
Publicado: (2015)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
por: Jamieson, Stephen M.F., et al.
Publicado: (2023)

“Paradoxical” findings of tumor vascularity and oxygenation in recurrent glioblastomas refractory to bevacizumab
por: Yamamoto, Yohei, et al.
Publicado: (2017)

Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma
por: Mao, Xing-gang, et al.
Publicado: (2016)

Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence
por: Christ, Sebastian M., et al.
Publicado: (2023)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Hypoxia-activated prodrug TH-302 decreased survival rate of canine lymphoma cells under hypoxic condition
por: Yamazaki, Hiroki, et al.
Publicado: (2017)

MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts
por: Zhang, Xiaomeng, et al.
Publicado: (2016)

Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
por: Reardon, D A, et al.
Publicado: (2012)

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
por: Jardim-Perassi, Bruna V., et al.
Publicado: (2021)

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
por: Ahluwalia, Manmeet S., et al.
Publicado: (2023)

Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
por: Kelly, William, et al.
Publicado: (2023)

Refractory Elevated Intracranial Pressure (ICP) in the Setting of a Traumatic Cerebral Sinus Venous Thrombosis (CSVT)
por: Kanakia, Kunal P, et al.
Publicado: (2021)

Pyruvate Induces Transient Tumor Hypoxia by Enhancing Mitochondrial Oxygen Consumption and Potentiates the Anti-Tumor Effect of a Hypoxia-Activated Prodrug TH-302
por: Takakusagi, Yoichi, et al.
Publicado: (2014)

Vascular dysfunction promotes regional hypoxia after bevacizumab therapy in recurrent glioblastoma patients
por: Gerstner, Elizabeth R, et al.
Publicado: (2020)

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
por: Ansstas, George, et al.
Publicado: (2016)

Bevacizumab for the Treatment of Glioblastoma
por: Gil-Gil, Miguel J., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ml2pso8g1gkj3g2rla0h4v060k